Michael Pehl, President and Chief Executive Officer joins Lisa to talk about Immunomedics.
Mr. Pehl joined Immunomedics in December 2017 as President and CEO. His decades of strategic, commercial and operational leadership experience has helped reconfigure the company’s organization to support commercialization efforts. He has built effective organizations, managed portfolios (pre-clinical, marketed, lifecycle management) and led business development efforts. Additionally, Mr. Pehl was instrumental in growing portfolios through partnerships, alliances and product acquisitions.
Mr. Pehl dedicated his career to building compassionate, trusted relationships with patients and customers, and providing groundbreaking therapies to improve patient outcomes. His philosophy revolves around the patient, which is at the center of all that he does. He understands that for patients fighting disease, every day counts.
Immunomedics is deeply committed to becoming the leading antibody drug conjugate (ADC) company worldwide, delivering breakthrough therapies to treat complex cancers and transform patient outcomes.
We will become a leading and integrated biopharmaceutical company dedicated to building, developing and commercializing a highly differentiated portfolio of targeted biologic therapies to transform patient outcomes based on clinical data and the deep scientific understanding of select solid tumor cancers and hematologic malignancies.